https://www.cancerresearchuk.org/about-cancer/treatment/drugs/durvalumab
Durvalumab (Imfinzi) | Cancer information | Cancer Research UK
Durvalumab is a type of immunotherapy. It is a treatment for lung cancer. Find out about how you have it, possible side effects and other important information.
cancer informationdurvalumabimfinziresearchuk
https://www.goodrx.com/imfinzi/medicare-coverage
Imfinzi Medicare Coverage and Co-Pay Details - GoodRx
Medicare coverage and pricing details for Imfinzi. Learn more about Medicare prescription drug plans and savings with GoodRx.
medicare coverageimfinzipaydetailsgoodrx
https://www.goodrx.com/imfinzi/what-is
Imfinzi (durvalumab)i: Dosage, Side Effects, Alternatives & More - GoodRx
Learn about Imfinzi (durvalumab) usage and dosing. Read the latest news and reviews about the drug as well as potential side effects and popular alternatives.
side effectsimfinzidurvalumabdosagealternatives
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-imfinzi-durvalumab-adult-patients-locally-advanced-or
FDA D.I.S.C.O. Burst Edition: FDA approval of Imfinzi (durvalumab) for adult patients with locally...
Listen to a soundcast of the September 2nd, 2022 FDA approval of Imfinzi (durvalumab) for adult patients with locally advanced or metastatic biliary tract...
d i s c o
https://www.miragenews.com/imfinzi-combo-boosts-survival-in-unresectable-1649619/
Imfinzi Combo Boosts Survival in Unresectable Liver Cancer | Mirage News
Positive high-level results from the EMERALD-3 Phase III trial showed AstraZeneca's Imfinzi (durvalumab) in combination with Imjudo (tremelimumab
liver cancerimfinzicomboboostssurvival
https://www.cancer.gov/news-events/cancer-currents-blog/2024/endometrial-cancer-durvalumab-pembrolizumab-chemotherapy
Imfinzi, Keytruda Approved for Some Endometrial Cancers - NCI
FDA has approved three new immunotherapy options, including pembrolizumab (Keytruda) and durvalumab (Imfinzi), with chemo for advanced endometrial cancer.
for someimfinzikeytrudaapprovedendometrial
https://www.medicines.org.uk/emc/product/9495/smpc
Imfinzi 50 mg/mL concentrate for solution for infusion - Summary of Product Characteristics (SmPC)...
Imfinzi 50 mg/mL concentrate for solution for infusion - Summary of Product Characteristics (SmPC) by AstraZeneca UK Limited